IN8bio, Inc. Common Stock (INAB) Stock Price

INABStock
$1.1747.79%52W
Market Cap$11.53M
P/E
PEG Ratio
Div yield
Beta0.38

INAB Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-41.01%
Price vs S&P 500 (4W)3.25%
VGM Score30.99

INAB Earnings Surprise History

Q2 25-1.24est. -1.80
Q3 25-0.85est. -1.25
Q4 25-0.45est. -0.47
Q1 26-0.26est. -0.69
Q2 26-0.25est. -0.37

INAB Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.10
4.10
4.10
4.10

Industry Peers — Biological Products(183)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
INABIN8bio, Inc. Common Stock
D$1.17
AMGNAmgen IncCCB$442.24
GILDGilead Sciences IncCBB$148.77
MRNAModerna, Inc. Common StockDCA$158.83
ARGXargenx SE American Depositary SharesDAB$1019.49
RVMDRevolution Medicines, Inc. Common StockFA$211.38
BIIBBiogen Inc. Common StockCDB$220.77
BNTXBioNTech SE American Depositary ShareCCB$114.05
NBIXNeurocrine Biosciences IncCBC$153.37
EXELExelixis IncCBB$56.72
HALOHalozyme Therapeutics, Inc.CBA$109.32

About IN8bio, Inc. Common Stock

IN8bio Inc is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for solid and liquid tumors using allogeneic, autologous, and engineered cell approaches. Lead programs include INB-400 for glioblastoma and INB-100 for high-risk leukemias, with additional candidates in earlier development stages.